Viatris Inc. and Ocuphire Pharma, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved RYZUMVI?? (phentolamine ophthalmic solution). RYZUMVI was evaluated in the comprehensive MIRA clinical trial program involving more than 600 subjects, including the MIRA-1 Phase 2b trial, MIRA-2 and MIRA-3 Phase 3 pivotal trials, and MIRA-4 Phase 3 pediatric trial.

RYZUMVI is an anti-microbial preservative-free, topical eye drop formulation of phentolamine ophthalmic solutions; the possibility that the Company may be unable to achieve expected benefits, synergies and operating efficiencies in connection with acquisitions, divestitures, or its global restructuring program, within the expected timeframe or at all; impairment charges or other losses related to the divestiture or sale of businesses or assets; the Company's failure to achieve expected or targeted future financial and operating performance and results; the potential impact of public health outbreaks, epidemics and pandemics, including the ongoing challenges and uncertainties posed by COVID-19; the scope, timing and outcome of any ongoing legal proceedings, and the impact of any such proceedings; any significant breach of data security or data or privacy or disruptions to the information technology systems; risks associated with international operations; the potential impact of international operations; and the impact of any ongoing legal proceedings; the scope, timing and outcomes of any ongoing legal procedures, and the impact of any any such proceedings; any significant breaches of data security or data privacy or disruptions to information technology systems; risk associated with international operations; and risk associated with international operations; the Company may be able to achieve a number of refractive eye disorder indications in partnership with Viatris.